Previous Article | Next Article 
Journal of Virology, December 1998, p. 9535-9543, Vol. 72, No. 12
0022-538X/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
Differential Intracellular Compartmentalization of Herpetic
Thymidine Kinases (TKs) in TK Gene-Transfected Tumor Cells: Molecular
Characterization of the Nuclear Localization Signal of Herpes
Simplex Virus Type 1 TK
Bart
Degrève,1,2
Magnus
Johansson,2
Erik
De
Clercq,1
Anna
Karlsson,2 and
Jan
Balzarini1,*
Laboratory of Virology and Chemotherapy, Rega
Institute for Medical Research, B-3000 Leuven,
Belgium,1 and
Division of Clinical
Virology, Department of Immunology, Microbiology, Pathology, and
Infectious Diseases, Karolinska Institute, S-141 86 Stockholm,
Sweden2
Received 24 June 1998/Accepted 14 August 1998
 |
ABSTRACT |
The thymidine kinases (TKs) of herpes simplex virus type 1 (HSV-1),
HSV-2, and varicella-zoster virus (VZV) were expressed in human
osteosarcoma cells as fusion proteins with the green fluorescent
protein (GFP), and their intracellular localizations were determined.
The three TK-GFP fusion products were localized in different
subcellular compartments of the transfected tumor cells. HSV-1 TK-GFP
was localized exclusively in the nucleus, HSV-2 TK-GFP was
predominantly found in the cytosol, while VZV TK-GFP was localized in
both the nucleus and the cytosol. In support of these findings, we
identified a nuclear localization signal (NLS) in the N-terminal
arginine-rich region of HSV-1 TK that was absent in HSV-2 and VZV TK.
The first 34 amino acids proved necessary for the specific nuclear
localization of HSV-1 TK and, when added to the VZV TK-GFP gene
construct, also sufficed to specifically target VZV TK-GFP to the
nucleus. Further analysis of this NLS through site-directed mutagenesis
revealed that the basic amino acid-rich nonapeptide
25R-R-T-A-L-R-P-R-R33 is of crucial importance
in the nuclear targeting of HSV-1 TK. In particular, we revealed that
the presence of the arginine residues at positions 25, 26, 30, 32, and
33 is obligatory for efficient NLS functioning, whereas arginine and
histidine residues outside of the nonapeptide (i.e., residues R18, R20,
and H22) did not change the functional properties of the NLS.
 |
INTRODUCTION |
The herpesviruses herpes
simplex virus type 1 (HSV-1), HSV-2, and varicella-zoster virus
(VZV) encode thymidine kinases (TKs), of which the broad substrate
specificity is the basis for the treatment of herpesvirus
infections. Indeed, the herpesvirus TKs phosphorylate several antiviral
nucleoside analogues, including (E)-5-(2-bromovinyl)-2'-deoxyuridine (BVDU) and
ganciclovir (17). The herpesvirus TKs also convert
antiherpetic drugs to cytostatic agents in TK gene-transfected tumor
cells (5-9, 18). The feasibility of a combined gene
therapy-chemotherapy approach for the treatment of cancer with HSV-1 TK
and ganciclovir is currently being investigated in clinical
trials for the treatment of brain tumors (16, 33, 38-41)
and ovarian cancer (22). In addition to their importance from a therapeutic viewpoint, herpesvirus thymidine kinases also appear
to be necessary for reactivation from latency (15, 20).
The herpesvirus TKs and the mammalian 2'-deoxyguanosine kinase (dGK),
2'-deoxycytidine kinase (dCK), and TK2 are sequence related
(4, 28-30). Johansson et al. (30) recently
expressed the mammalian deoxyribonucleoside kinases as fusion proteins
with the green fluorescent protein (GFP) (11, 48) to study
protein localization in living cells (36, 43). Unexpectedly,
they found dCK in the nuclear compartment of transfected cells
(30), whereas it was formerly believed to localize in the
cytosol (3). The literature on the intracellular
distribution of the herpesvirus TKs is rather confusing. Cheng and
Ostrander (14) found HSV-1 TK mainly in the cytosol of
HSV-1 infected HeLa TK
cells. Others detected HSV-1 TK
activity in nuclear extracts of HSV-1 TK gene-transfected cells but did
not measure TK activity in cytosol extracts (35). Haarr and
Flatmark (26), however, showed by an immunofluorescence
technique that HSV-1 TK was localized in the cytosol of HSV-1 infected
cells, and they found no TK activity in the nuclear extracts of these
cells. HSV-2 TK was found in the cytosol of HeLa TK
cells
infected with HSV-2 (14). Finally, fluorescent anti-VZV TK
antibodies predominantly stained the nuclei of VZV-infected HEL cells
(46).
We decided to study the intracellular localization of HSV-1, HSV-2, and
VZV TK as fusion proteins with GFP. We found that the TKs of three
herpesviruses, i.e., HSV-1, HSV-2, and VZV, were targeted to different
cellular compartments after transfection of the cells with the
corresponding TK-GFP fusion gene: HSV-1 TK was nuclear, HSV-2 TK was
cytosolic, and VZV TK was spread over the nucleus and cytosol. We
identified and further characterized a nuclear localization
signal (NLS) in the N-terminal domain of HSV-1 TK (i.e., amino
acids 1 to 34). We demonstrated that this newly identified NLS
sequence was both necessary for specific nuclear localization of
HSV-1 TK and sufficient to transport VZV TK (which we found localized
in both the nucleus and the cytosol) to the nucleus of NLS-VZV TK-GFP
fusion gene-transfected tumor cells. The HSV-1 TK NLS was further
characterized in detail through site-directed mutagenesis
experiments; the results of these experiments pointed to the crucial
role of the individual arginine residues at positions 25, 26, 30, 32, and 33 in NLS functioning.
 |
MATERIALS AND METHODS |
Cell culture.
Adherent human osteosarcoma cells deficient in
cytosol TK (designated OstTK
) were provided by M. Izquierdo (Universidad Autónoma de Madrid, Madrid, Spain). Cells
were maintained at 37°C in a humidified CO2-controlled
atmosphere in Eagle's minimal essential medium (Gibco, Paisley, United
Kingdom) supplemented with 10% heat-inactivated fetal calf serum (FCS)
(Integro, Zaandam, The Netherlands), 2 mM L-glutamine
(Gibco), 0.075% (wt/vol) NaHCO3 (Gibco), 0.5 µl of
geomycine (Gentamycin; 40 mg/ml; Schering-Plough) per ml, and 0.5 µl
of amphotericin B (Fungizone; 5 mg/ml; Bristol-Myers Squibb, Brussels,
Belgium) per ml.
Plasmid construction.
The bacterial strain for plasmid
constructions was Escherichia coli DH5
. The pRc/CMV/VZV
TK plasmid containing the VZV TK gene coding sequence was kindly
provided by J. Piette (University of Liège, Liège,
Belgium). The pMCTK and pGR18 plasmids (42) harboring the
HSV-1 TK and HSV-2 TK gene coding sequences, respectively, were kindly
provided by D. Ayusawa (Yokohama City University, Yokohama, Japan). The
following primers were obtained from Gibco or KEBO Lab (Stockholm,
Sweden). Primers 1, 3, 5, and 7 introduce an EcoRI
restriction site; primers 2, 4, and 6 introduce a SalI site;
primers 8, 9, and 10 introduce a PstI site; and primer 11 introduces a NotI site in the amplified PCR product (primer
1, 5'-GAGGAATTCATGTCAACGGATAAAACCGATG; primer 2, 5'-CTCGTCGACAGGGAAGTGTTGTCCTGAACGGC; primer 3, 5'-GAGGAATTCATGGCTTCGTACCCCGGCCATC; primer 4, 5'-CTCGTCGACAGGTTAGCCTCCCCCATCTCCCG; primer 5, 5'-GAGGAATTCATGGCTTCTCACGCCGGCCAAC; primer 6, 5'-CTCGTCGACAGAACTCCCCCCACCTCGCGGGC; primer 7, 5'-GAGGAATTCATGCAAGAAGCCACGGAAGTCCG; primer 8, 5'-GAGCTGCAGCTGCCGGCGAGGGCGCAAC; primer 9, 5'-CTCCTGCAGTCAACGGATAAAACCGATGTAAA; primer 10, 5'-GAGCTGCAGGTGAGCAAGGGCGAGGAGCTG; and primer 11, 5'-GAGGCGGCCGCTTTACTTGTACAGC). The VZV TK (primers 1 and 2),
HSV-1 TK (primers 3 and 4), and HSV-2 TK (primers 5 and 6) genes were
amplified by PCR from the appropriate plasmids. Upon cloning of the PCR
products in the pGEM-T vector (Promega Corp., Madison, Wis.), the
EcoRI-SalI TK fragments were excised and cloned
into the pEGFP-N1 N-Terminal Protein Fusion Vector (Clontech, Palo
Alto, Calif.). To produce the
(AA1-34) HSV-1 TK-GFP construct,
primers 7 and 4 were used to amplify the HSV-1 TK sequence lacking the
coding sequence for amino acids 1 to 34, which was subsequently cloned
into the pEGFP-N1 vector. The NLS-VZV TK-GFP vector was constructed by
ligating an EcoRI-PstI fragment (derived from the
HSV-1 TK gene by using primers 3 and 8) and a
PstI-SalI fragment (derived from the VZV TK gene
by using primers 9 and 2) together in an
EcoRI-SalI-cut pEGFP-N1 vector. To construct the
NLS-GFP vector, the aforementioned EcoRI-PstI
fragment (derived from the HSV-1 TK gene by using primers 3 and 8) and
a PstI-NotI fragment (derived from the GFP gene
by using primers 10 and 11) were ligated together in the
EcoRI-NotI-digested pEGFP-N1 vector.
Site-directed mutagenesis of putative NLS amino acids.
Eight
mutant HSV-1 TK-GFP constructs were prepared according to the
QuickChange site-directed mutagenesis kit (Stratagene, La Jolla,
Calif.) protocol. The primers used were designed in such a way that the
codons for the seven amino acid pairs were replaced by the
BamHI restriction site 5'-GGATCC-3' as follows: for the A17G-R18S mutations, sense primer
5'-CTGCGTTCGACCAGGCTGGATCCTCTCGCGGCCATAGCAAC and antisense
primer 5'-GTTGCTATGGCCGCGAGAGGATCCAGCCTGGTCGAACGCAG; for the
S19G-R20S mutations, sense primer
5'-CGACCAGGCTGCGCGTGGATCCGGCCATAGCAACCGAC and
antisense primer 5'-GTCGGTTGCTATGGCCGGATCCACGCGCAGCCTGGTCG; for the H22S mutation, sense primer
5'-GCTGCGCGTTCTCGCGGATCCAGCAACCGACGTACG and antisense primer
5'-CGTACGTCGGTTGCTGGATCCGCGAGAACGCGCAGC; for the R25G-R26S
mutations, sense primer 5'-CGGCCATAGCAACGGATCCACGGCGTTGCGCCC and antisense primer 5'-GGGCGCAACGCCGTGGATCCGTTGCTATGGCCG;
for the L29G-R30S mutations, sense primer
5'-GCAACCGACGTACGGCGGGATCCCCTCGCCGGCAGC and antisense primer
5'-GCTGCCGGCGAGGGGATCCCGCCGTACGTCGGTTGC; for the R32G-R33S
mutations, sense primer 5'-GGCGTTGCGCCCTGGATCCCAGCAAGAAGCCACG and antisense primer 5'-CGTGGCTTCTTGCTGGGATCCAGGGCGCAACGCC;
and for the E36G-A37S mutations, sense primer
5'-CTCGCCGGCAGCAAGGATCCACGGAAGTCCGCC and antisense primer
5'-GGCGGACTTCCGTGGATCCTTGCTGCCGGCGAG. In addition, one
insertion mutation was made, inserting 12 nucleotides between the L29
and R30 codons. The following two primers were used: sense primer
5'-GACGTACGGCGTTGGTGTCGACGGCTCGCCCTCGCCGGC and antisense
primer 5'-GCCGGCGAGGGCGAGCCGTCGACACCAACGCCGTACGTC.
After linear amplification of the mutant primers with Pfu
DNA polymerase (Stratagene) and wild-type HSV-1 TK-GFP vector as a
template in a temperature cycler program (30 s at 95°C, followed by
20 cycles of 30 s at 95°C, 1 min at 55°C, and 12 min at 68°C), wild-type plasmid was digested with DpnI restriction enzyme
(Stratagene), and the mutant DNA was transformed into competent
E. coli DH5
. Kanamycin-resistant colonies were screened
for mutant plasmids by SalI or BamHI restriction
digestion of the plasmid preparations.
Stable and transient transfection of tumor cells.
The
pEGFP-N1 vector and the herpesvirus TK-GFP fusion gene constructs were
introduced into OstTK
cells via membrane fusion-mediated
transfer by using plasmid-liposome complexes (LipofectAMINE reagent;
Gibco) as described by the supplier. Briefly, 2 µg of plasmid DNA and
5 µl of LipofectAMINE reagent, diluted in Opti-MEM I reduced serum
medium (Gibco) were used for each transfection of 500,000 cells in a
6-well plate (Nunc, Roskilde, Denmark). The stable TK-GFP fusion gene
transfectants shown in Fig. 1 and 3 were isolated by maintaining the
cell cultures in the presence of HAT medium (i.e., normal growth
medium, supplemented with 100 µM hypoxanthine, 0.4 µM aminopterin,
and 16 µM thymidine), while stably transfected GFP-expressing
OstTK
cells were isolated after selection in the presence
of 0.5 mg of Geneticin (Duchefa, Haarlem, The Netherlands) per ml.
Monoclonal transfected OstTK
cell lines were obtained by
plating the cells at clonal density in tissue culture plates (Corning,
N.Y.), after which single colonies were isolated and expanded. The
nuclear localization signal (NLS)-GFP fusion gene (Fig. 3) and the
mutant HSV-1 TK-GFP fusion genes (Fig. 4) were only transiently
transfected in OstTK
, as pictures were taken 24 h
after the transfection procedure. A standard fluorescein isothiocyanate
(FITC) filter-equipped fluorescence microscope was used.
HSV-1 and HSV-2 infection.
The procedure for the infection
of
(AA1-34) HSV-1 TK-GFP and HSV-2 TK-GFP fusion gene-expressing
OstTK
cells with HSV-1 (Lyons strain) and HSV-2 (G
strain), respectively, was adapted from the method of Andrei et al.
(2). Briefly, nearly confluent osteosarcoma cells, grown in
6-well plates (Nunc), were inoculated with various dilutions of virus
stock (prepared on HEL cells) in 2% FCS-containing medium. After a 2-h
adsorption period at 37°C, the medium was replaced by fresh 2%
FCS-containing medium, and the cells were further incubated at 37°C
in a humidified CO2-controlled atmosphere. Two days later,
viral plaques were evaluated under an FITC filter-equipped microscope.
 |
RESULTS |
Intracellular localization of herpesvirus TKs.
To study the
intracellular localization of HSV-1 TK, HSV-2 TK, and VZV TK, the
corresponding genes, fused to the GFP coding sequence in the pEGFP-N1
vector (Clontech), were transfected in human osteosarcoma cells
deficient in cytosolic TK (OstTK
). The fluorescence
pattern was subsequently evaluated with a FITC filter-equipped
fluorescence microscope. The wild-type pEGFP-N1 vector, encoding for
GFP, was included as a control. Expression of GFP in the
OstTK
cells showed, as expected, a strong fluorescence
signal in both the nucleus and the cytosol (Fig.
1A). When the HSV-1 TK-GFP fusion gene
was introduced into the OstTK
cells, fluorescence was
mainly observed in the nucleus (panel B). The visualization of the
nucleoli localize the presence of the HSV-1 TK-GFP fusion protein
inside the nucleus and not in association with the nuclear envelope.
The HSV-2 TK-GFP fusion product was localized in the cytosol, with no
fluorescence in the nucleus (panel C). However, VZV TK fused to GFP
showed essentially the same distribution pattern as that seen with
control GFP (panel D), i.e., fluorescence was detected both in the
nucleus and the cytosol to an equal degree.

View larger version (127K):
[in this window]
[in a new window]
|
FIG. 1.
Herpesvirus TKs fused with GFP. The pEGFP-N1 vector,
encoding for GFP, and the herpesvirus TK-GFP fusion constructs (shown
at the top of each panel) were transfected into OstTK
cells. After selection of stable transfectants, the fluorescence
pattern was evaluated by using an FITC filter-equipped fluorescence
microscope. Panels: A, Nonfused GFP; B, HSV-1 TK-GFP; C, HSV-2 TK-GFP;
D, VZV TK-GFP.
|
|
HSV-1 TK contains an N-terminal NLS necessary for transport to the
nucleus.
The observation that HSV-1 TK was localized in the
nucleus, HSV-2 TK was localized in the cytosol, and VZV TK was spread
over both the nucleus and cytosol suggested that an NLS was present in
the HSV-1 TK protein. In our search of an NLS in the HSV-1 TK (GenBank
database), we found that the N-terminal end (amino acids 1 to 34) of
the HSV-1 TK consists of a basic amino acid cluster containing seven
arginine residues (Fig. 2). Five of these arginine residues, which were localized within two clusters at positions 25 to 26 and at positions 30, 32, and 33 (with a proline residue present at position 31) closely resemble the bipartite consensus motif identified by Dingwall and Laskey (19) in
several nuclear proteins, although with a 3-amino-acid spacer instead of a 10-amino-acid spacer. In the homologous HSV-2 TK sequence, only
four arginine residues are present, while the VZV TK lacks the complete
N-terminal region homologous to the HSV-1 and HSV-2 TK sequence (Fig.
2). No crystallographic data are available on the N-terminal domain
(amino acids 1 to 34) of HSV-1 TK (10), and therefore it is
unknown how the seven arginine residues are spatially organized in this
part of the protein. However, due to the high content of charged amino
acids, it is most likely that these residues are exposed on the outer
surface of the enzyme, as is required for proper NLS functioning
(45).

View larger version (12K):
[in this window]
[in a new window]
|
FIG. 2.
Alignment of N-terminal ends of herpesvirus TKs. The
predicted amino acid sequences of HSV-1 TK, HSV-2 TK, and VZV TK were
aligned and are shown together with their respective amino acid
numbers. The amino acids are indicated by the one-letter code. Note
that the region homologous to the N-terminal part of HSV-1 TK and HSV-2
TK is absent in the VZV TK sequence.
|
|
In order to delineate the role of the HSV-1 TK N-terminal basic amino
acid cluster in the nuclear localization of the enzyme,
an HSV-1 TK-GFP
deletion mutant that lacks amino acids 1 to 34
[designated

(AA1-34)
HSV-1 TK-GFP] was constructed. The mutant
fusion protein was detected
in both the nucleus and the cytosol,
thereby resembling the control GFP
and the VZV TK-GFP fluorescence
pattern (Fig.
3A). This experiment
provided evidence that the
N-terminal 34 amino acids are indispensable
for the specific nuclear
localization of HSV-1 TK. To address the issue
whether it could
also target VZV TK to the nucleus, we linked the amino
acid 1
to 34 coding sequence of HSV-1 TK to the 5' end of the VZV
TK-GFP
fusion gene. The recombination mutant enzyme (designated NLS-VZV
TK-GFP) was localized in the nucleus (Fig.
3B), whereas the wild-type
VZV TK-GFP fusion protein was distributed in both the nucleus
and the
cytosol (compare with Fig.
1D). The recombinant NLS-GFP
gene was
constructed to confirm that the change to nucleoplasmic
localization of
the recombinant NLS-VZV TK-GFP depended solely
on the HSV-1 TK NLS
sequence and to ascertain that no specific
sequences of VZV TK were
involved. After transfection of the NLS-GFP
fusion gene into
OstTK

cells, fluorescence was predominantly observed in
the nucleus
(Fig.
3C).

View larger version (46K):
[in this window]
[in a new window]
|
FIG. 3.
The N-terminal NLS of HSV-1 TK. The HSV-1 TK gene
fragment encoding for the N-terminal 34 amino acids was deleted from
the HSV-1 TK-GFP construct and transferred to both the VZV TK-GFP
fusion gene and control GFP. The resulting GFP fusion constructs (shown
on top of each picture) were transfected into OstTK cells
and evaluated by using an FITC filter-equipped fluorescence microscope.
Panels: A, (AA1-34) HSV-1 TK-GFP; B, NLS-VZV TK-GFP; C, NLS-GFP.
|
|
Deletion of the nuclear localization fragment in HSV-1 TK-GFP is
not complemented by viral infection.
The intracellular
localization of HSV-1 TK, HSV-2 TK, and VZV TK raises the question as
to the reason for this remarkable difference in TK localization.
Expression of an individual viral protein in a transfected cell,
however, greatly differs from the naturally occurring situation, i.e.,
viral infection, where a large amount of additional viral proteins is
expressed. Morin et al. (37) showed complementation of a
nuclear localization defect in a mutant adenovirus DNA binding protein
by infection of cells with adenovirus encoding for the mutant protein.
One could hypothesize that the three related herpes TKs are all
transported to the nucleus by additional viral proteins during viral
infection, utilizing an NLS-independent mechanism. Therefore, the
(AA1-34) HSV-1 TK-GFP and HSV-2 TK-GFP-expressing cell lines were
infected with HSV-1 (Lyons) and HSV-2 (G), respectively, which gave
rise to virus-induced plaques in the infected monolayers that were surrounded by rounded cells. However, virus infection did not result in
the nuclear targeting of either
(AA1-34) HSV-1 TK-GFP or HSV-2
TK-GFP (data not shown).
Site-directed mutagenesis in the N-terminal NLS region.
In
order to further characterize the NLS function of the N-terminal end of
HSV-1 TK, a variety of mutations were introduced in this region,
namely, one insertion between L29 and R30 (comprising 12 nucleotides),
one single amino acid mutation at position 22, and six double amino
acid mutations (five double amino acid mutations within the region of
amino acids 1 to 34 and one double amino acid mutation just outside
this region). Mutation of each of the five amino acid pairs in the
identified NLS (i.e., A17G-R18S, S19G-R20S, R25G-R26S, L29G-R30S, and
R32G-R33S) resulted in the loss of one or two arginine residues in the
NLS. The double codons were designed in such a way that they were
replaced by the BamHI restriction site, thus encoding for
Gly-Ser and enabling rapid screening of mutants by restriction
analysis. The single amino acid mutation affects the histidine residue
at position 22, which is changed into a serine residue. The E36G-A37S
mutation localized outside the NLS served as a control. The
12-nucleotide insertion mutation (designated 29-VSTA-30) was chosen to
enlarge the distance between the R25-R26 and the R30-P31-R32-R33 basic
amino acid clusters.
The intracellular distributions of the eight mutant HSV-1 TK-GFP
constructs were determined after transfection into OstTK

cells (Fig.
4 and Table
1). The A17G-R18S, S19G-R20S, and H22S
mutants (Fig.
4A, B, and C, respectively) were exclusively localized
in
the nuclei of transfected cells, in a way similar to the wild-type
HSV-1 TK-GFP (Fig.
1B), indicating that the arginine residues
at
positions 18 and 20 and the histidine residue at position 22
are not
involved in the nuclear signaling of HSV-1 TK. In contrast,
the
insertion mutation and all double mutations between positions
25 and 33 (i.e., R25G-R26S, panel D; L29G-R30S, panel E; 29-VSTA-30,
panel F; and
R32G-R33S, panel G) resulted in a diffuse distribution
of both nuclear
and cytoplasmic fluorescence, pointing to the
importance of this whole
amino acid segment for the specific nuclear
targeting of HSV-1 TK. The
control double mutant (E36G-A37S) outside
the NLS domain gave
fluorescence that was exclusively localized
in the nucleus (Fig.
4H),
as was the case for wild-type HSV-1
TK-GFP.

View larger version (112K):
[in this window]
[in a new window]

View larger version (138K):
[in this window]
[in a new window]
|
FIG. 4.
Site-directed mutagenesis in the NLS of HSV-1 TK. The
mutant HSV-1 TK-GFP fusion constructs (shown at the top of each panel)
were transfected into OstTK cells and evaluated by using
an FITC filter-equipped fluorescence microscope. Panels: A, A17G-R18S
mutation; B, S19G-R20S mutation; C, H22S mutation; D, R25G-R26S
mutation; E, L29G-R30S mutation; F, 29-VSTA-30 insertion; G, R32G-R33S
mutation; H, E36G-A37S mutation.
|
|
 |
DISCUSSION |
We found that the TKs of three evolutionarily related
herpesviruses (i.e., the alpha-herpesviruses HSV-1, HSV-2, and VZV) fused with GFP were localized in different compartments of transfected OstTK
cells. Expression of HSV-1 TK-GFP in
OstTK
cells gave rise to nuclear fluorescence. After
transfection of the HSV-2 TK-GFP fusion gene in tumor cells,
fluorescence was observed almost exclusively in the cytosol, whereas
VZV TK fused to GFP was distributed throughout the cell (i.e., in both
the nucleus and cytosol) and showed the same distribution pattern as
the nonfused (control) GFP (Fig. 1).
The expression of the herpetic TKs in different cellular compartments
was surprising given the fact that all herpesviruses replicate in the
nuclear compartments of cells. Therefore, the localization of the TKs
of the various herpesviruses was not expected to differ from one
another. On the other hand, there is no evidence that a cytosolic
2'-deoxynucleotide (dNTP) pool physically separated from a nuclear dNTP
pool may exist. Therefore, it may not be important whether the TK is
expressed in the nucleus or in the cytosol. In fact, HSV TK-dependent
nucleoside analogues, such as BVDU and GCV, were not found to differ in
their cytostatic activity against HSV TK gene-transfected tumor cells,
irrespective of the compartment in which the viral TK gene was
expressed (unpublished observations). The same statement could hold for
the sensitivity to antiviral nucleoside analogues of herpesviruses
expressing either nuclear or cytosolic TK and will be the subject of
further study. Johansson et al. (30) recently reached
similar conclusions on dCK and the 2'-deoxycytidine (dCyd) nucleotide
pools. They found that there was no difference in the cytostatic
activity of dCK-dependent nucleoside analogues whether the dCK was
expressed in the nuclear or in the cytosolic compartment. Thus, due to
the fact that there is no evidence that the nucleus and the cytosol
have separate dNTP pools, the biological meaning of the different
localization of HSV-1, HSV-2, and VZV TKs in the cellular compartments
is currently unclear. To obtain additional insights into the
significance of compartmentation of the viral TKs, it would now also be
of particular interest to reveal whether deletion of the HSV-2 TK
N-terminal region has an effect on the intracellular location of the
HSV-2 TK and whether an artificial NLS can be constructed at the N
terminus by the substitution of nonbasic residues into arginine
residues in a way that is analogous to that of the HSV-1 TK primary
amino acid sequence.
HSV TK was demonstrated to play a pivotal role in latency. Indeed,
TK-deficient HSV strains, although able to establish latent infections
in mouse trigeminal ganglia, cannot reactivate from latency (15,
20). This dependence of reactivation on TK activity may be
explained by the requirement for sufficiently high pools of pyrimidine
deoxyribonucleotides to permit viral DNA replication in nonreplicating
neurons. Recently, Chen and coworkers showed that human TK1 can
functionally replace the HSV-1 TK for reactivation of latent virus
(13). It is well known that human TK1 is located predominantly in the cytosol (3, 27), as was also shown
recently by Johansson et al. with a TK1-GFP fusion construct
(30). In addition, both HSV-1 and HSV-2 depend on TK
activity for reactivation, yet HSV-1 TK and HSV-2 TK showed completely
different intracellular targeting. Therefore, it seems unlikely that
the nuclear localization of HSV-1 TK is crucial for reactivation and
also that changing the intracellular localization of HSV-1 TK from the
nucleus to the cytosol (by deleting the NLS) would affect the
reactivation capacity of the virus.
Many nuclear targeting sequences have been identified. As for the
targeting of proteins to cellular compartments other than the nucleus,
there does not exist a strict NLS consensus motif. Some general
characteristics have been deduced for nuclear localization signals (for
an overview, see reference 23): (i) they usually consist of short amino acid sequences, containing a high proportion of
positively charged amino acids (lysine and/or arginine), often flanked
by a proline residue; (ii) unlike mitochondrial targeting signals, they
are not localized at specific sites within the protein; (iii) they are
not removed after nuclear entry; and (iv) they can coexist with other
NLSs within the same protein. The seven-amino-acid stretch
P-K-K-K-R-K-V of simian virus 40 large T antigen (SV40T-ag) has served
as the prototype NLS (25, 31, 34), and many other nuclear
import signals were identified on the basis of sequence homology with
the SV40T-ag NLS. Chelsky et al. (12) proposed the
four-residue consensus sequence K-R/K-X-R/K. Later, Robbins et al.
(44) and Dingwall and Laskey (19) described a
bipartite motif, defined as a pair of basic residues separated by a
spacer region of any 10 amino acids from a second basic cluster
downstream in which at least three of five amino acids are basic.
Johansson and coworkers (30) identified a nuclear targeting
signal of human dCK representing a "classical" bipartite consensus
motif and showed that this signal was required for nuclear import of this protein. The nuclear localization of dCK is the first evidence of
a mammalian deoxyribonucleoside kinase being localized in the nucleus.
We have now provided evidence that also HSV-1 TK is localized in the
nucleus, and we have identified an amino acid stretch in HSV-1 TK that
represents the nuclear targeting signal. The NLS that we identified in
the N-terminal region of HSV-1 TK is different from the known
"classical" NLS consensus motifs (Fig. 2). When the first 34 amino
acids of the HSV-1 TK were deleted, the resulting mutant HSV-1 TK-GFP
fusion protein [
(AA1-34) HSV-1 TK-GFP] became diffusely localized
in both the nucleus and the cytosol, whereas the wild-type HSV-1 TK-GFP
showed a specific nuclear localization. We also demonstrated that this
NLS was sufficient to target VZV TK and GFP to the nucleus when linked
to the 5'-terminal end of the VZV TK and GFP genes, respectively (Fig.
3). The site-directed mutagenesis studies that we have performed on the
NLS revealed a nine-amino acid stretch within the NLS
(25R-R-T-A-L-R-P-R-R33) that, following
replacement of any of the arginine residues, lost its nuclear targeting
function. In contrast, mutations of amino acids outside but near this
nonapeptide sequence did not affect the nuclear signaling, pointing to
the importance of the five-arginine cluster in the NLS identified
above. In addition, we showed that the spatial configuration of these
five arginines is important to the functioning of the NLS, since the
insertion of four extra amino acids within the nonapeptide again
destroyed the NLS-driven targeting of the TK to the nucleus.
It could be argued that the intracellular localization of the native
herpesvirus TKs (not fused with GFP) should be visualized by using
immunofluorescence techniques instead of visualizing the TK-GFP fusion
proteins in transfected cells. However, since the introduction of GFP,
numerous reports have been published showing the correct nuclear
localization of proteins that are fused with GFP and known to reside in
the nucleus (e.g., corticoid receptors [21, 24],
histones [32, 47], topoisomerases [1], etc.). Moreover, it seems unlikely that the GFP
moiety had a significant effect on overall protein folding. Indeed,
GFP-linked HSV-1 TK proved to be still enzymatically active in the
intact cells, since many antiherpes compounds were highly cytostatic in
the HSV-1 TK-GFP gene-transfected tumor cells (unpublished results).
Also, GFP-linked TK purified from TK-GFP overexpressing bacterial cell
cultures did phosphorylate thymidine and BVDU to a marked extent (data
not shown). Taken together with our conclusive data obtained on
deletion, insertion, and mutagenesis of the HSV-1 TK NLS, we believe
that the GFP fusion protein methodology for determining
intracellular TK localization is consistent and reliable.
In conclusion, we have shown that, despite their close relationship,
HSV-1 TK, HSV-2 TK, and VZV TK are localized in different intracellular
compartments of TK-GFP fusion gene-transfected tumor cells. We have
shown that the N-terminal 34 amino acids of HSV-1 TK are necessary and
sufficient for its specific nuclear localization. This newly identified
NLS does not represent a classical NLS motif but is nevertheless
sufficient to specifically target the otherwise uniformly distributed
VZV TK to the nucleus. Detailed analysis of the HSV-1 TK NLS by
site-directed mutagenesis points to the nonapeptide
25R-R-T-A-L-R-P-R-R33 as being essential for
the nuclear targeting of HSV-1 TK.
 |
ACKNOWLEDGMENTS |
We thank Graciela Andrei and Robert Snoeck for help with the
herpesvirus infection experiments and Christiane Callebaut for dedicated editorial help.
This work was supported by Project 3.0180.95 from the Belgian
Fonds Voor Geneeskundig Wetenschappelijk Onderzoek (B.D., E.D.C., and J.B.), Project 95/5 from the Belgian Geconcerteerde
Onderzoeksacties (B.D., E.D.C., and J.B.), the Swedish Medical Research
Council (A.K. and M.J.), the Medical Faculty of Karolinska Institute
(A.K. and M.J.), and the Harald and Greta Jeansson Foundation (A.K. and
M.J.). Bart Degrève is the recipient of an IWT fellowship from
the Vlaams Instituut voor de bevordering van het
Wetenschappelijk-Technologisch onderzoek in de Industrie.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Rega Institute
for Medical Research, Katholieke Universiteit Leuven,
Minderbroedersstraat 10, B-3000 Leuven, Belgium. Phone: 32-16-337352. Fax: 32-16-337340. E-mail:
jan.balzarini{at}rega.kuleuven.ac.be.
 |
REFERENCES |
| 1.
|
Adachi, N.,
M. Miyaike,
S. Kato,
R. Kanamaru,
H. Koyama, and A. Kikuchi.
1997.
Cellular distribution of mammalian DNA topoisomerase II is determined by its catalytically dispensable C-terminal domain.
Nucleic Acids Res.
25:3135-3142[Abstract/Free Full Text].
|
| 2.
|
Andrei, G.,
R. Snoeck,
P. Goubau,
J. Desmyter, and E. De Clercq.
1992.
Comparative activity of various compounds against clinical strains of herpes simplex virus.
Eur. J. Clin. Microbiol. Infect. Dis.
11:143-151[Medline].
|
| 3.
|
Arnér, E. S. J., and S. Eriksson.
1995.
Mammalian deoxyribonucleoside kinases.
Pharmacol. Ther.
67:155-186[Medline].
|
| 4.
|
Balasubramaniam, N. K.,
V. Veerisetty, and G. A. Gentry.
1990.
Herpesviral deoxythymidine kinases contain a site analogous to the phosphoryl-binding arginine-rich region of porcine adenylate kinase: comparison of secondary structure predictions and conservation.
J. Gen. Virol.
71:2979-2987[Abstract/Free Full Text].
|
| 5.
|
Balzarini, J.,
E. De Clercq,
D. Ayusawa, and T. Seno.
1985.
Murine mammary FM3A carcinoma cells transformed with the herpes simplex virus type 1 thymidine kinase gene are highly sensitive to the growth-inhibitory properties of (E)-5-(2-bromovinyl)-2'-deoxyuridine and related compounds.
FEBS Lett.
185:95-100[Medline].
|
| 6.
|
Balzarini, J.,
E. De Clercq,
A. Verbruggen,
D. Ayusawa,
K. Shimizu, and T. Seno.
1987.
Thymidylate synthase Is the principal target enzyme for the cytostatic activity of (E)-5-(2-bromovinyl)-2'-deoxyuridine against murine mammary carcinoma (FM3A) cells transformed with the herpes simplex virus type 1 and type 2 thymidine kinase gene.
Mol. Pharmacol.
32:410-416[Abstract].
|
| 7.
|
Balzarini, J.,
C. Bohman, and E. De Clercq.
1993.
Differential mechanism of cytostatic effect of (E)-5-(2-bromovinyl)-2'-deoxyuridine, 9-(1,3-dihydroxy-2-propoxymethyl)guanine, and other antiherpetic drugs on tumor cells transfected by the thymidine kinase gene of herpes simplex virus type 1 or type 2.
J. Biol. Chem.
268:6332-6337[Abstract/Free Full Text].
|
| 8.
|
Balzarini, J.,
C. Bohman,
R. T. Walker, and E. De Clercq.
1994.
Comparative cytostatic activity of different antiherpetic drugs against herpes simplex virus thymidine kinase gene-transfected tumor cells.
Mol. Pharmacol.
45:1253-1258[Abstract].
|
| 9.
|
Balzarini, J.,
K. W. Morin,
E. E. Knaus,
L. I. Wiebe, and E. De Clercq.
1995.
Novel (E)-5-(2-iodovinyl)-2'-deoxyuridine derivatives as potential cytostatic agents against herpes simplex virus thymidine kinase gene transfected tumors.
Gene Ther.
2:317-322[Medline].
|
| 10.
|
Brown, D. G.,
R. Visse,
G. Sandhu,
A. Davies,
P. J. Rizkallah,
C. Melitz,
W. C. Summers, and M. R. Sanderson.
1995.
Crystal structures of the thymidine kinase from herpes simplex virus type-I in complex with deoxythymidine and ganciclovir.
Nat. Struct. Biol.
2:876-881[Medline].
|
| 11.
|
Chalfie, M.,
Y. Tu,
G. Euskirchen,
W. W. Ward, and D. C. Prasher.
1994.
Green fluorescent protein as a marker for gene expression.
Science
263:802-805[Abstract/Free Full Text].
|
| 12.
|
Chelsky, D.,
R. Ralph, and G. Jonak.
1989.
Sequence requirements for synthetic peptide-mediated translocalization to the nucleus.
Mol. Cell. Biol.
9:2487-2492[Abstract/Free Full Text].
|
| 13.
|
Chen, S.-H.,
W. J. Cook,
K. L. Grove, and D. M. Coen.
1998.
Human thymidine kinase can functionally replace herpes simplex virus type 1 thymidine kinase for viral replication in mouse sensory ganglia and reactivation from latency upon explant.
J. Virol.
72:6710-6715[Abstract/Free Full Text].
|
| 14.
|
Cheng, Y.-C., and M. Ostrander.
1976.
Deoxythymidine kinase induced in HeLa TK cells by herpes simplex virus type I and type II. II. Purification and characterization.
J. Biol. Chem.
251:2605-2610[Abstract/Free Full Text].
|
| 15.
|
Coen, D. M.,
M. Kosz-Vnenchak,
J. G. Jacobson,
D. A. Leib,
C. L. Bogard,
P. A. Schaffer,
K. L. Tyler, and D. M. Knipe.
1989.
Thymidine kinase-negative herpes simplex virus mutants establish latency in mouse trigeminal ganglia but do not reactivate.
Proc. Natl. Acad. Sci. USA
86:4736-4740[Abstract/Free Full Text].
|
| 16.
|
Culver, K. W.,
J. Van Gilder,
C. J. Link,
T. Carlstrom,
T. Buroker,
W. Yuh,
K. Koch,
K. Schabold,
S. Doornbas, and B. Wetjen.
1994.
Gene therapy for the treatment of malignant brain tumors with in vivo tumor transduction with the herpes simplex thymidine kinase gene/ganciclovir system.
Hum. Gene Ther.
5:343-379[Medline].
|
| 17.
|
De Clercq, E.
1993.
Antivirals for the treatment of herpesvirus infections.
J. Antimicrob. Chemother.
32:121-132.
|
| 18.
|
Degrève, B.,
G. Andrei,
M. Izquierdo,
J. Piette,
K. Morin,
E. E. Knaus,
L. I. Wiebe,
I. Basrah,
R. T. Walker,
E. De Clercq, and J. Balzarini.
1997.
Varicella-zoster virus thymidine kinase gene and antiherpetic pyrimidine nucleoside analogues in a combined gene/chemotherapy treatment for cancer.
Gene Ther.
4:1107-1114[Medline].
|
| 19.
|
Dingwall, C., and R. A. Laskey.
1991.
Nuclear targeting sequences a consensus?
Trends Biochem. Sci.
16:478-481[Medline].
|
| 20.
|
Efstathiou, S.,
S. Kemp,
G. Darby, and A. C. Minson.
1989.
The role of herpes simplex virus type 1 thymidine kinase in pathogenesis.
J. Gen. Virol.
70:869-879[Abstract/Free Full Text].
|
| 21.
|
Fejes-Toth, G.,
D. Pearce, and A. Naray-Fejes-Toth.
1998.
Subcellular localization of mineralocorticoid receptors in living cells: effects of receptor agonists and antagonists.
Proc. Natl. Acad. Sci. USA
95:2973-2978[Abstract/Free Full Text].
|
| 22.
|
Freeman, S. M.,
C. McCune,
W. Robinson,
C. N. Abboud,
G. N. Abraham,
C. Angel, and A. Marrogi.
1995.
The treatment of ovarian cancer with a gene modified cancer vaccine: a phase I study.
Hum. Gene Ther.
6:927-939[Medline].
|
| 23.
|
Garcia-Bustos, J.,
J. Heitman, and M. N. Hall.
1991.
Nuclear protein localization.
Biochim. Biophys. Acta
1071:83-101[Medline].
|
| 24.
|
Georget, V.,
J. M. Lobaccaro,
B. Terouanne,
P. Mangeat,
J. C. Nicolas, and C. Sultan.
1997.
Trafficking of the androgen receptor in living cells with fused green fluorescent protein-androgen receptor.
Mol. Cell. Endocrinol.
129:17-26[Medline].
|
| 25.
|
Goldfarb, D. S.,
J. Gariepy,
G. Schoolnik, and R. D. Kornberg.
1986.
Synthetic peptides as nuclear localization signals.
Nature
332:641-644.
|
| 26.
|
Haarr, L., and T. Flatmark.
1987.
Evidence that deletion of coding sequences in the 5' end of the thymidine kinase gene of herpes simplex virus type 1 affects the stability of the gene products.
J. Gen. Virol.
68:2817-2829[Abstract/Free Full Text].
|
| 27.
|
He, Q.,
S. Skog,
N. Wang,
S. Eriksson, and B. Tribukait.
1996.
Characterization of a peptide antibody against a C-terminal part of human and mouse cytosolic thymidine kinase, which is a marker for cell proliferation.
Eur. J. Cell. Biol.
70:117-124[Medline].
|
| 28.
|
Johansson, M., and A. Karlsson.
1996.
Cloning and expression of human deoxyguanosine kinase cDNA.
Proc. Natl. Acad. Sci. USA
93:7258-7262[Abstract/Free Full Text].
|
| 29.
|
Johansson, M., and A. Karlsson.
1997.
Cloning of the cDNA and chromosome localization of the gene for human thymidine kinase 2.
J. Biol. Chem.
272:8454-8458[Abstract/Free Full Text].
|
| 30.
|
Johansson, M.,
S. Brismar, and A. Karlsson.
1997.
Human deoxycytidine kinase is localized in the cell nucleus.
Proc. Natl. Acad. Sci. USA
94:11941-11945[Abstract/Free Full Text].
|
| 31.
|
Kalderon, D.,
B. L. Roberts,
W. D. Richardson, and A. E. Smith.
1984.
A short amino acid sequence able to specify nuclear localization.
Cell
39:499-509[Medline].
|
| 32.
|
Kanda, T.,
K. F. Sullivan, and G. M. Wahl.
1998.
Histone-GFP fusion protein enables sensitive analysis of chromosome dynamics in living mammalian cells.
Curr. Biol.
8:377-385[Medline].
|
| 33.
|
Kun, L. E.,
A. Gajjar,
M. Muhlbauer,
R. L. Heideman,
R. Sanford,
M. Brenner,
A. Walter,
J. Langston,
J. Jenkins, and S. Facchini.
1995.
Stereotactic injection of herpes simplex thymidine kinase vector producer cells (PA317-G1Tk1SvNa.7) and intravenous ganciclovir for the treatment of progressive or recurrent primary supratentorial pediatric malignant brain tumors.
Hum. Gene Ther.
6:1231-1255[Medline].
|
| 34.
|
Lanford, R. E., and J. S. Butel.
1984.
Construction and characterization of an SV40 mutant defective in nuclear transport of T antigen.
Cell
37:801-813[Medline].
|
| 35.
|
Lee, C. G.,
C. G. Kim,
R. Namkung,
S. E. Lee, and S. D. Park.
1990.
Transfection of mouse cells with thymidine kinase gene of herpes simplex virus.
Cytotechnology
3:141-147[Medline].
|
| 36.
|
Levy, J. P.,
R. R. Muldoon,
S. Zolotukhin, and C. J. Link.
1996.
Retroviral transfer and expression of a humanized, red-shifted green fluorescent protein gene into human tumor cells.
Nat. Biotechnol.
14:610-614[Medline].
|
| 37.
|
Morin, N.,
C. Delsert, and D. F. Klessig.
1989.
Nuclear localization of the adenovirus DNA-binding protein: requirement for two signals and complementation during viral infection.
Mol. Cell. Biol.
9:4372-4380[Abstract/Free Full Text].
|
| 38.
|
Oldfield, E. H.
1993.
Gene therapy for the treatment of brain tumors using intra-tumoral transduction with the thymidine kinase gene and intravenous ganciclovir.
Clinical Protocols. Hum. Gene Ther.
4:36-69.
|
| 39.
|
Raffel, C.,
K. Culver,
D. Kohn,
M. Nelson,
S. Siegel,
F. Gillis,
C. J. Link, and J. G. Villablanca.
1994.
Gene therapy for the treatment of recurrent pediatric malignant astrocytomas with in vivo tumor transduction with the herpes simplex thymidine kinase gene/ganciclovir system.
Hum. Gene Ther.
5:863-890[Medline].
|
| 40.
|
Ram, Z.,
K. W. Culver,
S. Walbridge,
J. A. Frank,
R. M. Blaese, and E. H. Oldfield.
1993.
Toxicity studies of retroviral-mediated gene transfer for the treatment of brain tumors.
J. Neurosurg.
79:400-407[Medline].
|
| 41.
|
Ram, Z.,
K. W. Culver,
E. Oshiro,
J. J. Viola,
H. L. DeVroom,
E. Otto,
Z. Long,
Y. Chiang,
G. J. McGarrity,
L. M. Muul,
D. Katz,
R. M. Blaese, and E. H. Oldfield.
1997.
Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells.
Nat. Med.
12:1354-1361.
|
| 42.
|
Reyes, G. R.,
K.-T. Jeang, and G. S. Hayward.
1982.
Transfection with the isolated herpes simplex virus thymidine kinase gene. I. Minimal size of the active fragments from HSV-1 and HSV-2.
J. Gen. Virol.
62:191-206[Abstract/Free Full Text].
|
| 43.
|
Rizzuto, R.,
M. Brini,
P. Pizzo,
M. Murgia, and T. Pozzan.
1995.
Chimeric green fluorescent protein as a tool for visualizing subcellular organelles in living cells.
Curr. Biol.
5:635-642[Medline].
|
| 44.
|
Robbins, J.,
S. Dilworth,
R. A. Laskey, and C. Dingwall.
1991.
Two interdependent basic domains in nucleoplasmin nuclear targeting sequence: identification of a class of bipartite nuclear targeting sequence.
Cell
64:615-623[Medline].
|
| 45.
|
Roberts, B. L.,
W. D. Richardson, and A. E. Smith.
1987.
The effect of protein context on nuclear localization signal function.
Cell
50:465-475[Medline].
|
| 46.
|
Shiraki, K.,
T. Ogino,
K. Yamanishi, and M. Takahashi.
1985.
Immunochemical characterization of pyrimidine kinase induced by varicella-zoster virus.
J. Gen. Virol.
66:221-229[Abstract/Free Full Text].
|
| 47.
|
Ushinsky, S. C.,
H. Bussey,
A. A. Ahmed,
Y. Wang,
J. Friesen,
B. A. Williams, and R. K. Storms.
1997.
Histone H1 in Saccharomyces cerevisiae.
Yeast
13:151-61[Medline].
|
| 48.
|
Youvan, D. C., and M. E. Michel-Beyerle.
1996.
Structure and fluorescence mechanism of GFP.
Nat. Biotechnol.
14:1219-1220[Medline].
|
Journal of Virology, December 1998, p. 9535-9543, Vol. 72, No. 12
0022-538X/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Gill, M. B., Kutok, J. L., Fingeroth, J. D.
(2007). Epstein-Barr Virus Thymidine Kinase Is a Centrosomal Resident Precisely Localized to the Periphery of Centrioles. J. Virol.
81: 6523-6535
[Abstract]
[Full Text]
-
Gill, M. B., Murphy, J.-E., Fingeroth, J. D.
(2005). Functional Divergence of Kaposi's Sarcoma-Associated Herpesvirus and Related Gamma-2 Herpesvirus Thymidine Kinases: Novel Cytoplasmic Phosphoproteins That Alter Cellular Morphology and Disrupt Adhesion. J. Virol.
79: 14647-14659
[Abstract]
[Full Text]
-
Naesens, L., Lenaerts, L., Andrei, G., Snoeck, R., Van Beers, D., Holy, A., Balzarini, J., De Clercq, E.
(2005). Antiadenovirus Activities of Several Classes of Nucleoside and Nucleotide Analogues. Antimicrob. Agents Chemother.
49: 1010-1016
[Abstract]
[Full Text]
-
Ray, P., De, A., Min, J.-J., Tsien, R. Y., Gambhir, S. S.
(2004). Imaging Tri-Fusion Multimodality Reporter Gene Expression in Living Subjects. Cancer Res.
64: 1323-1330
[Abstract]
[Full Text]
-
Degrève, B., Esnouf, R., De Clercq, E., Balzarini, J.
(2001). Mutation of Gln125 to Asn Selectively Abolishes the Thymidylate Kinase Activity of Herpes Simplex Virus Type 1 Thymidine Kinase. Mol. Pharmacol.
59: 285-293
[Abstract]
[Full Text]
-
Perozzo, R., Jelesarov, I., Bosshard, H. R., Folkers, G., Scapozza, L.
(2000). Compulsory Order of Substrate Binding to Herpes Simplex Virus Type 1 Thymidine Kinase. A CALORIMETRIC STUDY. J. Biol. Chem.
275: 16139-16145
[Abstract]
[Full Text]
-
Zheng, X., Johansson, M., Karlsson, A.
(2000). Retroviral Transduction of Cancer Cell Lines with the Gene Encoding Drosophila melanogaster Multisubstrate Deoxyribonucleoside Kinase. J. Biol. Chem.
275: 39125-39129
[Abstract]
[Full Text]